Endocrinology Research and Practice · Published 2026-01-07 · DOI 10.5152/erp.2025.25743
Objective: The present investigation sought to explore the potential link between serum bisphenol A (BPA)—a well-recognized endocrine-disrupting agent—and diabetic peripheral polyneuropathy (PNP) among patients diagnosed with type 2 diabetes mellitus (DM). Methods: Eighty patients underwent clinical and electrophysiologic assessment of PNP and singletime- point serum BPA quantification by enzyme-linked immunosorbent assay. Results: The average age and diabetes duration did not differ significantly between patients with PNP and those without. However, fasting glucose, glycosylated hemoglobin (HbA1c), and triglyceride levels were notably elevated in the PNP group relative to non-PNP patients. But serum BPA levels were not statistically different between the groups. Serum BPA levels were negatively correlated with the glomerular filtration rate and HbA1c and positively correlated with the body mass index and highdensity lipoprotein cholesterol levels. Conclusion: No significant association was observed between serum BPA concentrations and the presence of PNP in patients with type 2 DM. These results confirm that known vascular risk factors such as glycemic control are closely related to the presence of PNP. Cite this article as: Sali S, Kiyici S, Ustundag Y, et al. The relationship between serum bisphenol a levels and diabetic peripheral polyneuropathy in patients with type 2 diabetes mllitus. Endocrinol Res Pract. 2026;30(1):23-29.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →